A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)
170 Park Ave, Florham Park NJ
- Tweets 282
- Following 257
- Followers 7,171
- Likes 6
RELEASE: Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law
Read the full release here:
globenewswire.com/news-relea…
1
1
3
217
RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics.
Read the full release here:
globenewswire.com/news-relea…
1
4
333
RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Read the full release here: globenewswire.com/news-relea…
1
2
322
RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.
globenewswire.com/news-relea…
4
5
475
RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
READ THE FULL RELEASE HERE:
globenewswire.com/news-relea…
161
Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions.
Read the full release here: globenewswire.com/news-relea…
5
8
653
We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses.
globenewswire.com/news-relea…
1
5
14
1,018
RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Read it here:
globenewswire.com/news-relea…
1
7
15
1,134
Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
globenewswire.com/news-relea…
2
2
11
1,094
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read the full release here: globenewswire.com/news-relea…
1
4
9
853
An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer.
Read the full release - with link to the publication - here:
globenewswire.com/news-relea…
1
4
589
Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: globenewswire.com/news-relea…
1
5
612
We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. globenewswire.com/news-relea…
1
5
621
A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.)
indd.adobe.com/view/d551a70e…
2
10
1,108
Celularity, Inc. is proud to be a member of the MASS Coalition, a group of business leaders who together are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease. saveourwoundcare.org/media/
1
2
7
864
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million!
Read the full release here:
globenewswire.com/news-relea…
1
3
11
930
Exciting news! We have added to our portfolio of placental-derived advanced biomedical products with the acquisition of Rebound. The full release can be read here: globenewswire.com/news-relea…
1
3
469
Celularity's CEO, Dr. Robert Hariri, was interviewed on the Health Care Rounds Podcast, discussing Celularity's cutting-edge innovations, and the future of medicine. The episode is out now and linked below.
piped.video/9KmpAGyMRQM?si=2IQb…
3
533
Excited about the growth we’ve been experiencing at Celularity. Expecting a 290% growth over the first half of 2023 in the first half of 2024. On track for the 510(k) submission of our Celularity Tendon Wrap in 2025. It’s an exciting time at Celularity! tinyurl.com/y7jzjdz8
3
2
3
565
Amplifying our success through strategic partnerships and collaboration: In this clip from Celularity's Investor & Analyst R&D presentation, our CEO elaborates on how our internal talent allows for collaboration and partnerships with leading companies and academic institutions.
3
1
4
742
A World Class Facility for Commercial Scale Manufacturing: In this clip from Celularity's Investor & Analyst R&D day presentation, our CEO Dr. Robert Hariri describes the capabilities and opportunities of our manufacturing infrastructure.
#biotech #stemcells
2
1
2
807
A clip from Celularity's recent Investor and Analyst R&D Day presentation. #stemcells #stemcelltherapy
The whole presentation is available here:
piped.video/2w2EwQ1xmlo?feature…
2
2
5
643
Presented data at the ASCO Annual Meeting further demonstrating the potential of combining our placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-treat cancers. globenewswire.com/news-relea…
3
1
3
353
If you missed our Research & Development Day presentation yesterday, you can watch it in its entirety via the link below. It's a firsthand look at current breakthroughs, opportunities, and strategies delivered by our leadership team. celularity.com/investor-rela…
2
6
8,284
Great data helping differentiate the placenta as a source of cells for immunotherapy, and demonstrating the valuable potential of our placental platform for allogeneic CAR-T products. globenewswire.com/news-relea…
1
3
8
691
Our CEO, Dr. Robert Hariri, with an exclusive on Global Market Bulletin discussing exciting advancements in cellular medicine and the work we're doing here at Celularity. piped.video/BiqFi4rwQcc?si=yyGe…
4
406
Announcing our first on-site and virtual Investor and Analyst R&D Day at our world-class headquarters, research, and manufacturing center! globenewswire.com/news-relea…
3
1
3
368
Excited to present the potential of our decellularized placental biomaterials in tendon management and healing at the ORS Tendon Conference. globenewswire.com/news-relea…
1
271
We're hiring! If you have the deep intellectual curiosity, drive and determination it takes to forge new frontiers in cell therapy and regenerative medicine, visit our Celularity Linkedin page and check out the Jobs listings!
1
1
428
Data in @Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knock out in allogeneic stromal cells leads to significantly lower TF expression, activity, and thrombotic effects. Exciting news for the safety of ASC-based #celltherapy.
bit.ly/3qjvHua
ALT Abstract scientific image of allogeneic stromal cells
1
3
359
This morning, our CEO, Dr. Robert Hariri, wrote a letter to shareholders about advisory guidance from @TamerHolding regarding anticipated purchase orders this year in the range of $60-$80 million. Read the letter here: bit.ly/3VR0Hx3
1
534
Today we announced that @DrBobHariri, the Company’s CEO, Chairman and Founder, kick off the International Precision Medicine Center (IPMC) Conference, April 11-12th, in Goyang City, Republic of Korea, along with @ScottGottliebMD #IPMC23
Read more here: bit.ly/3KoVB5R
2
3
70
13,641
Today we announced an oral presentation at the upcoming 2023 Annual Meeting Society for Biomaterials, which will be held April 19–22 in San Diego, CA. @SFBiomaterials #SFB2023
Read the full announcement here: bit.ly/40DTa6v
2
4
72
19,677
Today we announced that we received notice that the FDA’s Office of Combination Products (OCP) completed its preliminary product classification and jurisdictional assessment of Celularity’s investigational FUSE Bone Void Filler.
Read the full announcement here: bit.ly/40C0q2C
4
77
31,532
Today we announced we entered into an exclusive distribution agreement with AD Ports Logistics (ADPL) in partnership with CH Trading Group to distribute our biomaterial products in the UAE, Qatar, Bahrain, Oman, Kuwait, and Egypt. Read the full announcement here: bit.ly/3JNrAfO
7
83
19,651
Today we announced the @US_FDA has agreed with our recommendation that our investigational Celularity Tendon Wrap (CTW) product should be regulated as a device by the FDA Center for Devices and Radiologic Health (CDRH).
Read the full announcement here: bit.ly/3HIHNTQ
2
8
723
Today we announced the results of a strategic review of our 2023 key initiatives.
Read more: bit.ly/3wvCTTG
#biotechnology #placenta #crohns #aml #fshd #osteoarthritis #mlasc #nkcell #tcell #cycart19
1
6
782
Today we announced an exclusive distribution agreement with the Tamer Group, a leading Middle East healthcare distribution company, for our Halal-Certified regenerative biomaterial products in Saudi Arabia.
Read the full announcement here: bit.ly/3CIYag7
2
766
Today we announced that we have entered into an exclusive territory distribution agreement with CH Trading Group, to act as the exclusive territories distributor of Celularity’s Halal-Certified products in more than 100 countries. Read more: bit.ly/3VZpj5f
1
3
588
Today we announced a re-analysis of long term follow-up data from three of our legacy studies showed clinically meaningful benefit and durable biological effect in patients with moderate to severe Crohn’s disease warranting further investigation: bit.ly/3ZfpRqv #JPM23
6
880
Today we announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer. Read the full announcement here: bit.ly/3WIdUYB
2
546
The Circle H Sharia Advisory Council issues @celularity a groundbreaking ruling for conditional permitted use of stem cells, exosomes, and biomaterials in research, clinical trials and treatment.
Read more: bit.ly/3WfOXUq
1
5
1,003
Today @DrBobHariri released a letter to all stockholders to share some thoughts about @Celularity’s work in #osteoarthritis (OA), an important disease in which we are conducting preclinical work.
To learn more, click here: bit.ly/3PAnwC5
6
872
We’re excited to share that @Celularity has received Halal Certification of our cellular therapeutics, biomaterial products & business model, opening access to Islamic markets globally.
To learn more, click here: bit.ly/3H5tuc3
1
4
Today we presented data from preclinical studies of our placental-derived CYCART-19 T cells in combination with @TeamImugene’s onCARlytics (CF33-CD19) oncolytic virus at SITC. Read the full press release on our website: bit.ly/3NWEIB1
#SITC #Celularity #BioTech
7
32
Today we reported our third quarter 2022 financial results and provided a corporate update. Read the press release and hear from our CEO Robert Hariri, M.D., Ph.D. on our website: bit.ly/3G0p31M
2
9
Today we announced that we will present preclinical data on the development of our cell therapy program CYNK-101 in combination with avelumab at The Society for Immunotherapy of Cancer (SITC). Read the release on our website: bit.ly/3UNqXXH
#SITC #Celularity #BioTech
7
Today we announced that John R. Haines has been promoted to Senior EVP, General Manager and Chief Administrative Officer, and Brad Glover, Ph.D., has been promoted to EVP and Chief Operating Officer. Read the full press release here: bit.ly/3SWn0Pg
1
Today we announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed as our new EVP, CMO and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. Read the full announcement here: bit.ly/3RlUVzP
1
Today we announced that @DrBobHariri will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET. Click here to read the full announcement: bit.ly/3dGFa8P
2
7